Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laith J Abu-Raddad

Showing results (271-280 of 318) with videos related to

Pageof 32
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2020
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure SettingLaith J Abu-Raddad, Hiam Chemaitelly, Joel A Malek, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Scientific Reports|March 19, 2021
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemicLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|January 28, 2022
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infectionsLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|August 9, 2022
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineageHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Scientific Reports|June 5, 2021
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence populationGheyath K Nasrallah, Soha R Dargham, Farah Shurrab, et al.
Influenza and Other Respiratory Viruses|November 29, 2023
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort studyMai A Mahmoud, Houssein H Ayoub, Peter Coyle, et al.
Journal of Global Health|February 9, 2022
Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experienceRaghid Bsat, Hiam Chemaitelly, Peter Coyle, et al.
Pageof 32

Showing results (271-280 of 318) with videos related to

Sort By:
Pageof 32
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2020
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure SettingLaith J Abu-Raddad, Hiam Chemaitelly, Joel A Malek, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Scientific Reports|March 19, 2021
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemicLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|January 28, 2022
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infectionsLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|August 9, 2022
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineageHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Scientific Reports|June 5, 2021
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence populationGheyath K Nasrallah, Soha R Dargham, Farah Shurrab, et al.
Influenza and Other Respiratory Viruses|November 29, 2023
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort studyMai A Mahmoud, Houssein H Ayoub, Peter Coyle, et al.
Journal of Global Health|February 9, 2022
Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experienceRaghid Bsat, Hiam Chemaitelly, Peter Coyle, et al.
Pageof 32